Clear Cell Renal Cell Carcinoma

It’s only the beginning.

Adjuvant therapy with pembrolizumab following nephrectomy conferred significant improvement in OS compared with placebo among adults with renal cell carcinoma who had a high risk for disease recurrence, study results showed.

MADRID — MEDI5752, a novel bispecific antibody binding to CTLA-4 and PD-1, showed potential as a first-line treatment in patients with advanced clear cell renal cell carcinoma, according to data presented at ESMO Congress.

MADRID — Moshe Ornstein, MD, discussed the results of LITESPARK-005 presented at ESMO Congress in a video interview with Healio.

NASHVILLE, Tenn. — Zanzalintinib monotherapy showed promising antitumor activity among patients with previously treated clear cell renal cell carcinoma, according to findings presented at International Kidney Cancer Symposium: North America.

NASHVILLE, Tenn. — An analysis of germline susceptibility to renal cell carcinoma revealed considerable heterogeneity, according to findings presented at International Kidney Cancer Symposium: North America.

NASHVILLE, Tenn. — Belzutifan exhibited efficacy at two doses for patients with advanced clear cell renal cell carcinoma, according to randomized phase 2 study results presented at International Kidney Cancer Symposium: North America.

NASHVILLE, Tenn. — Venous tumor thrombus appeared associated with elevated rates of pulmonary metastasis among patients with clear cell renal cell carcinoma, according to study results.

MADRID — In this video with Healio, Tian Zhang, MD, talked about “the bench-to-bedside journey of belzutifan” highlighted in the LITESPARK-005 study.

MADRID — Toni Choueiri, MD, talked with Healio about some of the new kidney cancer data “that could be practice-changing and, for sure, practice-informing” presented at ESMO Congress.